Highly skilled and experienced analytical scientists working in well equipped, GMP compliant laboratories.
Agenda1 is a specialist contract analytical company. We deliver high quality analytical support to companies across a wide range of industries, including Pharmaceutical, Healthcare, Medical Device and many others.
We are distinguished by our wide range of techniques, and our ability to support work from initial Method Development, through to final Product Release. We are cGMP compliant and ISO 9001:2008 certified and have been MHRA-inspected. View our quality page for further details.
Companies we work for range from internationally recognised major pharmaceutical and healthcare companies, through to well established drug product and fine chemical manufacturers and include a number of venture capital funded start ups as well as household names.
On site equipment is available to support Materials Characterisation, Chromatography and Wet Chemistry analysis. Equipment is maintained and qualified to meet cGMP requirements.
Techniques available include: X-Ray Powder Diffraction, Specific Surface Area (BET), Meso-Porosity, Particle Size Distribution by Sympatec and Malvern (dry powders and suspensions)
Techniques available include:
X-Ray Diffraction (XRD), Crystallinity / Amorphicity determination, Polymorph identification, Thermal Analysis (TGA) , Dynamic Vapour Sorption (DVS), Moisture and Volatiles content, Differential Scanning Calorimetry (DSC)
Techniques available include: Trace and Major Elemental Analysis, including metals (ICP OES/MS and X-Ray Fluorescence (XRF) and TOC for carbon
Techniques available include:High Pressure Liquid Chromatography (including UHPLC) and MS at Analytical Semi-Prep and Preparative scales.
Techniques available include: Headspace and liquid injection GC-FID / GC-MS / HS-GC.
Techniques available include:
Corrosion testing, Oil and Lubricant analysis, wide ranging Microscopy techniques (SEM, SEM-EDAX and Optical and RAMAN (Spectroscopy and Microscopy) Tapped / Bulk and True Density.
We provide a wide range of analytical services, including method development, verification and validation. We also support ad hoc investigations.
We have wide experience developing methods for the Pharmaceutical, Medical Device and Healthcare industry sectors.
We are familiar with working with teams carrying out method validation work to meet regulatory requirements, and for internal cGMP needs.
Method verification is used to demonstrate that a standardised published method (e.g. Pharmacopoeial method) can be run effectively in a given laboratory.
We are able to support a full range of standard ICH conditions with both on site and off site qualified storage facilities.
We support release testing for clinical studies and more routine release.
As a company with a wide range of experience, particularly in the development field, we are used to working in multi-disciplinary teams across the UK and well beyond.
Many times our clients have their own teams of scientists. What they don’t always have is spare time and capacity to focus on particularly difficult analytical challenges.
Our API-Optimisation support picks up from the moment the Chem Dev synthesis team deliver the API powder to the Pharm Dev team.
The focus here moves from API to a dose form that can be trialled in pre-clinical studies. But, before moving to that Pre Clinical Formulation work, we can provide support that can help you make your decisions faster, and more precisely.
Salt screening is an important part of any drug development programme, both as part of an IP review and also to understand the benefits (or otherwise) associated with using different salt forms.
Polymorphism in pharmaceuticals may be defined as the ability of a drug substance to exist in two or more crystalline forms.
Identifying options suitable for oral, parenteral or transdermal administration at an early stage brings time-saving and cost benefits to the entire programme.
Our experience has been employed by a wide range of industries, additional examples are available.
The Bone substitute market has seen dramatic growth over the last few years, and is forecast to continue to grow. Our expertise has grown in line with market demand.
Concept Life Sciences unveils new Analytical Science Hub in Bradford to cope with growing demand
Concept Life Sciences has acquired a new building on the Listerhills Science Park in Bradford to accommodate its growing workforce. The current facility which is home to Agenda1 (part of the Concept Life Sciences group), comprises both laboratories and offices, and due to increasing client demand has reached full capacity. In order to meet the […]
Delivering Quantitative Metals Testing by ICP OES
Summary Agenda1 were selected by the client to assist them with the analysis of their product to develop and validate a method for quantitative metals analysis by ICP-OES in accordance with USP 232 and 233. The client is an international company supplying high quality drug products. In this industry the cost of manufacturing drug products […]
Validation of 18 Analytical Methods to Support Pulmonary Product Development
Challenge The client was developing a pMDI drug product with a complex multi-stage manufacturing process involving API re-crystallization and particle size reduction steps . Wide-ranging validated analytical methods (physical, solid-state, chromatographic) were required to release AP I at various stages of the manufacturing process and to support research activities. Agenda 1 was able to deliver […]
Agenda1 has very much enjoyed the recent process of recruiting to its first Graduate Recruitment Programme. Historically, vacancies at Agenda1 have been filled in the traditional way; that is, by candidates who have already been in work and who are able to demonstrate competence for the job required. However, as the company continues to evolve […]
If it ain’t broke, DO fix it!
As a company providing outsourced services, I believe I should practise what I preach, so recently I’ve been looking for outsourced HR and H&S support.
By trawling the available websites, I soon picked up on a common benefit – nearly all these companies have decided to sell on…fear.
Taken for Granted?
Should the availability of a grant make any difference to what a commercially focussed company does? That question came to mind recently, as I was being interviewed by a university researcher looking at the impact of two different grant schemes from which we benefited. Partly I want to argue that a grant shouldn’t make any difference, but I recognise that if that were the case then the question “why do grant schemes exist at all?” leaps to the fore.